山西医科大学学报2018，Vol.49Issue(4)：342-346,5.DOI:10.13753/j.issn.1007-6611.2018.04.003
索非布韦对治疗慢性丙肝及缓解肝脏纤维化的临床研究
Clinical study on sofosbuvir in treatment of chronic hepatitis C and liver fibrosis
摘要
Abstract
Objective To explore the curative efficacy,safety of sofosbuvir and its inhibitory effect on liver fibrosis in hepatitis C patients.Methods The chronic hepatitis C patients without liver cirrhosis were selected from November 2016 to September 2017 in the Department of General Surgery of Tangdu Hospital,and randomly divided into control group and observation group.The patients in control group were treated with subcutaneous injection of pegylated interferon alpha-2a 180 g/week,and oral Leigh Bhave Lin 1 000 mg/d for 12 weeks.The patients in observation group were treated with oral sofosbuvir 400 mg/d and oral Leigh Leigh Bhave Lin 1 000 mg/d for 12 weeks.At the same time,40 chronic hepatitis C patients with decompensated cirrhosis patients were treated with oral sofosbuvir 400 mg/d and Leigh Bhave Lin 1 000 rng/d for 12 weeks.The level of HCV-RNA in serum of patients were analyzed at week 12 and 24 after treatment,the virologic response and sustained response were detected,the adverse reactions were observed during the medication,and the serum procollagen (PC Ⅲ) and hyaluronic acid (HA) level were measured to evaluate the level of liver fibrosis.Results There was no statistically significant difference in baseline data between the two groups.After treatment for 12 weeks,the rate of virological response was 82.5％ in control group and 95.0％ in observation group.The curative rate was higher in observation group than in control group(P ＜ 0.01).At week 24,the continuous negative rate of serum HCV-RNA was 72.5％ in control group and 90.0％ in observation group(P＜0.01).At week 24,PCⅢ level and HA level significantly decreased(P ＜0.01).Conclusion Compared with pegylated interferon alpha-2a,sofosbuvir may have better efficacy for chronic hepatitis C with less adverse effect and higher safety.Sofosbuvir can effectively inhibit the progression of liver fibrosis.关键词
索非布韦/聚乙二醇干扰素/慢性丙肝/病毒学应答/肝纤维化Key words
sofosbuvir/pegylated interferon/chronic hepatitis C/virological response/hepatic fibrosis分类
医药卫生引用本文复制引用
陈安,杨振宇,杜锡林,代柏树,鲁建国..索非布韦对治疗慢性丙肝及缓解肝脏纤维化的临床研究[J].山西医科大学学报,2018,49(4):342-346,5.基金项目
国家自然科学基金资助项目(8117287) （8117287）
陕西省科技创新工程基金资助项目(2015KTCL03-05) （2015KTCL03-05）
